New drug shrinks tumors in some breast cancer patients
NCT ID NCT04699630
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested a drug called patritumab deruxtecan in 121 people with advanced or metastatic breast cancer. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The main goal was to see how many patients had their tumors shrink or disappear. Results showed some patients responded, but side effects were also reported.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Patritumab deruxtecan (U3-1402)
What this could lead to
If successful, this drug could offer a new treatment option for people with metastatic breast cancer, especially those who have not responded to other therapies.
What could go wrong
This is a phase 2 trial with only 121 participants, so results may not apply to everyone. Side effects are possible, and the drug may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Florida Cancer Specialists-North
St. Petersburg, Florida, 33705, United States
-
Florida Cancer Specialists-South
Fort Myers, Florida, 33901, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Highlands Oncology Group
Springdale, Arkansas, 72762, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Rutgers-Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35249, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States